Zanos, Panos http://orcid.org/0000-0002-1968-8648
Thompson, Scott M.
Duman, Ronald S.
Zarate, Carlos A. Jr.
Gould, Todd D.
Funding for this research was provided by:
National Institute of Mental Health (MH107615, MH086828)
Harrington Discovery Institute Scholar-Innovator grant
Article History
First Online: 7 March 2018
Compliance with Ethical Standards
:
: This work was supported by a National Institutes of Health Grant (MH107615) and a Harrington Discovery Institute Scholar-Innovator Grant to Todd D. Gould, and a National Institutes of Health Grant (MH086828) to Scott M. Thompson.
: Todd D. Gould has received consulting fees from Janssen Pharmaceuticals, and research funding from Janssen Pharmaceuticals and Roche Pharmaceuticals during the preceding 3 years. Ronald S. Duman has received consulting fees from Janssen Pharmaceuticals and Taisho, and research funding from Janssen Pharmaceuticals and Taisho, Allergan, Naurex, Navitor, and Relmada during the preceding 3 years. Carlos A. Zarate Jr. is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation. Panos Zanos, Carlos A. Zarate Jr., and Todd D. Gould are listed as co-authors in patent applications related to the pharmacology and use of (<i>2S,6S</i>)- and (<i>2R,6R</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. Scott M. Thompson is listed as a co-inventor on a patent application for the use of negative allosteric modulators of GABA<sub>A</sub> receptors containing alpha 5 subunits as fast-acting antidepressants.